CANCER DRUGS FUND AND SUNITINIB

That this House is deeply concerned that the drug Sunitinib, which is significant in the treatment of some cancers, is excluded by the Cancer Drugs Fund for kidney cancer, including for its cause and direct complications; notes that this has led to members of the public being denied life-saving treatment despite the drug being routinely available on the NHS and acknowledged as effective; further notes the specific case of Mr Adrian Steel in Leicester, who will have to pay a total of £46,806 to continue using the drug he has experienced significant success with in the past; and calls on the Government to review how these crucial treatments are prescribed and to review the exclusions in place for this particular example.